Dementia
Also known as: Senility
Methodology & AI Transparency ⓘ
Dementia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is dementia? Dementia is a loss of mental functions that is severe enough to affect your daily life and activities.
- 2 Real-world patient consensus: Clinical coding for Dementia uses ICD-10 F03.90 across Memory & Cognition specialty care.
- 3 Typical cash cost range: Clinicians assessing Dementia focus on neurovascular unit dysfunction [Dementia F03.90] and targeted history.
- 4 Top reported side effects / signs: Longitudinal Dementia monitoring tracks MoCA Cognitive Screening in Dementia (F03.90: Score) toward >= 26 / 30 (F03.90).
Ask our AI Specialists anything about Dementia
What Is Dementia?
What is dementia? Dementia is a loss of mental functions that is severe enough to affect your daily life and activities. These functions include: Memory Language skills Visual perception (your ability to make sense of what you see) Problem solving Trouble with everyday tasks The ability to focus and pay attention It is normal to become a bit more forgetful as you age. But dementia is not a normal part of aging. It is a serious disorder that interferes with your daily life. What are the types of dementia? The most common types of dementia are known as neurodegenerative disorders. These are diseases in which the cells of the brain stop working or die.
Pathophysiology, Underlying Causes & Clinical Presentation
In Dementia (F03.90), physiological disruption stems from neurovascular unit dysfunction [Dementia F03.90], Cross-referenced with NIH MeSH (Dementia), informing Alzheimer, Dementia & Memory Health protocols that track Homocysteine & Vitamin in Dementia (F03.90: B12) (Homocysteine < 9 umol/L; B12 > 500 pg/mL (F03.90)).
Common Symptoms & Clinical Signs
- • Visual perception (your ability to make sense of what you see)
- • Trouble with everyday tasks
- • Presentation of Dementia (F03.90): slowed processing speed in Dementia (F03.90: compared with prior)
- • Secondary Dementia clinical sign: short-term recall difficulty in Dementia (F03.90: for recent conversations,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Dementia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F03.90 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Alzheimer, Dementia & Memory Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: MoCA Cognitive Screening in Dementia (F03.90: Score) | >= 26 / 30 (F03.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Homocysteine & Vitamin in Dementia (F03.90: B12) | Homocysteine < 9 umol/L; B12 > 500 pg/mL (F03.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Fasting in Dementia (F03.90: ApoB / HbA1c) | Optimal cardiometabolic neuroprotection (F03.90) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Dementia
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Donepezil Hydrochloride Aricept • RxCUI 997229 | Cholinesterase Inhibitor | 94% | $0.0427 | $ 5.60 /mo |
| Galantamine Hydrobromide Razadyne • RxCUI 860901 | Cholinesterase Inhibitor | 74% | $0.8856 | $ 7.62 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Dementia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Brexpiprazole With Antidepressants for Agitation in Alzheimer's Dementia: Post In this exploratory post hoc analysis, brexpiprazole improved agitation symptoms and was generally well tolerated in participants with Alzheimer's dementia with and without concomitant antidepressants. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry • 2026-11-15 • Phase III Randomized Trial | N = 97 | 88/100 | PMID 42502037 ↗ |
| Can This Approach Help? Inside the Latest Research on Donanemab treatment effect by baseline tau burden and disease severity: Donanemab-mediated slowing of disease progression occurred across baseline tau PET and plasma P-tau217 levels. Alzheimer's & dementia : the journal of the Alzheimer's Association • 2026-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42273802 ↗ |
| New Insights on Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical: What a 204-Participant Study Found Liraglutide was generally safe and well tolerated in non-diabetic patients with Alzheimer's disease. Nature medicine • 2026-01-15 • Randomized Controlled Trial | N = 204 | 88/100 | PMID 41326666 ↗ |
| Can This Approach Help? Inside the Latest Research on Brexpiprazole's impacts on patients and caregivers in agitation in Alzheimer's At Week 10, the differences of brexpiprazole 1 and 2 mg versus placebo for NPI total score were -1.2 (p = 0.5891) and -8.4 (p < 0.0001), and those for NPI-Distress total score were -1.1 (p = 0.2292) and -3.9 (p < 0.0001),... Alzheimer's & dementia : the journal of the Alzheimer's Association • 2025-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40717666 ↗ |
| Can This Approach Help? Inside the Latest Research on Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate The measurements used for the assessment of apathy in patients with AD had a high degree of overlap with the DCA. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry • 2021-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 32565008 ↗ |
Dementia Patient Community & “People Like Me” Threads
Filter Dementia community threads and patient logs by age, biological sex, dosage, and treatment duration.